[Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
We assessed correlation between the elimination of methotrexate administered in dose 3 g/m2 during consolidation phase and the early complications in 129 children treated for acute lymphoblastic leukemia. Among 500 chemotherapy cycles included in the analysis the elimination of methotrexate was delayed in 66 (13.2%) cycles in 43 (33.3%) of patients. Influence of methotrexate on selected liver and renal function tests was analyzed. We made an attempt of early identification of patients with high risk for delayed methotrexate elimination and subsequent toxicities.
Cwliklińska
Magdalena
M
Klinika Onkologii i Hematologii Dzieciecej P-A Instytutu Pediatrii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
Balwierz
Walentyna
W
Nowak
Jacek
J
Stanuch
Helena
H
D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D006801:Humans; D007223:Infant; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008727:Methotrexate / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012189:Retrospective Studies
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate